Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Baloxavir Marboxil→

Baloxavir Marboxil Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
1985606-14-1
Molecular formula
C27H23F2N3O7S
Molecular weight
571.6 g/mol
Drug class
Antiviral prodruginfluenza virus cap-dependent endonuclease inhibitor precursor
Mechanism of action
Baloxavir marboxil is converted to baloxavir acid, which inhibits the cap-dependent endonuclease of the influenza virus polymerase acidic (PA) protein, preventing viral mRNA synthesis and replication.
Indications / reported uses
  • Treatment of acute uncomplicated influenza in patients aged 5 years and older who are otherwise healthy or at high risk of influenza complications under the US label
  • Post-exposure prophylaxis of influenza in eligible patients aged 5 years and older; product- and jurisdiction-specific

Sources: US DailyMed — XOFLUZA · FDA — XOFLUZA label · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Baloxavir Marboxil Environmental Risk Assessment (ERA) (the Baloxavir Marboxil ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.